NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

BSX

104.66

-1.96%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

BSX

104.66

-1.96%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

BSX

104.66

-1.96%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

BSX

104.66

-1.96%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

BSX

104.66

-1.96%↓

Search

Johnson and Johnson

Geschlossen

BrancheGesundheitswesen

170.73 -0.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

169.57

Max

171.52

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.5B

5.5B

Verkäufe

1.9B

24B

KGV

Branchendurchschnitt

17.797

40.048

EPS

2.77

Dividendenrendite

2.98

Gewinnspanne

23.321

Angestellte

138,100

EBITDA

-9.1B

6.5B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.11% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.98%

2.45%

Nächstes Ergebnis

14. Okt. 2025

Nächste Dividendenausschüttung

9. Sept. 2025

Nächstes Ex-Dividendendatum

26. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

23B

400B

Vorheriger Eröffnungskurs

170.96

Vorheriger Schlusskurs

170.73

Nachrichtenstimmung

By Acuity

35%

65%

120 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Juli 2025, 16:47 UTC

Ergebnisse

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16. Juli 2025, 18:08 UTC

Market Talk
Ergebnisse

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16. Juli 2025, 17:27 UTC

Market Talk
Ergebnisse

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16. Juli 2025, 17:17 UTC

Market Talk
Ergebnisse

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16. Juli 2025, 16:34 UTC

Market Talk
Ergebnisse

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16. Juli 2025, 13:27 UTC

Ergebnisse

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16. Juli 2025, 10:32 UTC

Ergebnisse

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16. Juli 2025, 10:22 UTC

Ergebnisse

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Sales $23.74B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q EPS $2.29 >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16. Juli 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

5.11% Vorteil

12-Monats-Prognose

Durchschnitt 175.88 USD  5.11%

Hoch 190 USD

Tief 160 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

8

Buy

10

Halten

0

Sell

Technischer Score

By Trading Central

154.93 / 155.895Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

120 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.